Education
About Us
Working with TipRanks
Follow Us
PAVmed Inc (PAVM)
NASDAQ:PAVM
PAVM Stock Chart & Stats
$0.28
-$0.02(-2.96%)
At close: 4:00 PM EST
$0.28
-$0.02(-2.96%)
Day’s Range― - ―
52-Week Range$0.30 - $0.90
Previous CloseN/A
Volume127.06K
Average Volume (3M)377.79K
Market Cap
$8.99M
Enterprise Value$34.62M
Total Cash (Recent Filing)$3.10M
Total Debt (Recent Filing)$9.28M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Mar 31, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding29,671,925
10 Day Avg. Volume774,204
30 Day Avg. Volume377,786
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.43
Price to Sales (P/S)2.03
P/FCF Ratio-0.18
Enterprise Value/Market Cap3.85
Enterprise Value/Revenue509.14
Enterprise Value/Gross Profit-70.95
Enterprise Value/Ebitda-3.96
Forecast
1Y Price Target
$20.00Price Target Upside7042.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercialization GrowthLucid's high growth and ramp up in commercialization will be a major catalyst for PAVmed’s stock.
Financial ValuationCurrent valuation attractive: Maintaining a BUY rating, but raising the 12-month price target to $20 from $19 based on a NPV analysis.
Strategic PartnershipPAVM entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center to advance the Veris Health platform.
Bears Say
Development ChallengesPAVmed’s devices still have long development and commercialization challenges ahead.
Revenue PerformancePAVM reported 2Q25 results with revenue below consensus and GAAP loss per share significantly wider than expectations.
Technology IntegrationTechnology integration challenges may delay patient enrollment and weigh on top-line growth through 2026.
PAVmed News
PAVM FAQ
What was PAVmed Inc’s price range in the past 12 months?
PAVmed Inc lowest stock price was $0.30 and its highest was $0.90 in the past 12 months.
What is PAVmed Inc’s market cap?
PAVmed Inc’s market cap is $8.99M.
When is PAVmed Inc’s upcoming earnings report date?
PAVmed Inc’s upcoming earnings report date is Mar 31, 2026 which is in 101 days.
How were PAVmed Inc’s earnings last quarter?
PAVmed Inc released its earnings results on Nov 13, 2025. The company reported -$0.29 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.12.
Is PAVmed Inc overvalued?
According to Wall Street analysts PAVmed Inc’s price is currently Undervalued.
Does PAVmed Inc pay dividends?
PAVmed Inc does not currently pay dividends.
What is PAVmed Inc’s EPS estimate?
PAVmed Inc’s EPS estimate is -0.18.
How many shares outstanding does PAVmed Inc have?
PAVmed Inc has 29,671,925 shares outstanding.
What happened to PAVmed Inc’s price movement after its last earnings report?
PAVmed Inc reported an EPS of -$0.29 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -10.256%.
Which hedge fund is a major shareholder of PAVmed Inc?
Currently, no hedge funds are holding shares in PAVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PAVmed Inc
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
PAVM Company Deck
PAVM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several significant achievements, including successful Medicare endorsement for EsoGuard, strong financial positioning for Lucid, and strategic partnerships for Veris. However, challenges remain in debt restructuring and stagnant EsoGuard revenue growth.View all PAVM earnings summariesPAVM Stock 12 Month Forecast
Average Price Target
$20.00
▲(7042.86% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
Co-Diagnostics
―
Tenon Medical, Inc.
―
Heart Test Laboratories, Inc.
―
Ownership Overview
4.68% Insiders
0.93% Mutual Funds
2.64% Other Institutional Investors
91.14% Public Companies and
Individual Investors